SEP 10, 2019
In this interview from ASRS 2019, Dr. Nancy Holekamp explains how the HARBOR study informs the relationship between intraretinal fluid, subretinal fluid and visual outcomes. The trial included patients who were treated with ranibizumab for wet AMD. Patients with persistent subretinal fluid had significantly better visual acuity compared with those who had completely resolved subretinal fluid. Conversely, eyes with persistent intraretinal fluid had significantly worse vision than eyes lacking fluid. Although she posits explanations for these findings, the reason for these observations is still unclear.
Relevant Financial Disclosures: Dr. Holekamp is a consultant for and receives lecture fees and grant support from Genentech.